Document is current
Any future updates will be listed below
-
Authors
Jiang, Hua
Fu, Denggang
Pasupuleti, Santhosh Kumar https://orcid.org/0000-0001-5770-7187
Ramdas, Baskar https://orcid.org/0009-0006-2206-5720
Long, Alan https://orcid.org/0000-0002-9600-326X
Ramadan, Abdulraouf M.
Yang, Jinfeng
Kumar, Ramesh https://orcid.org/0000-0002-7545-4619
Hartman, Jessica H.
Kendrick, B. Jacob https://orcid.org/0000-0001-9435-4720
Simpson, Ed https://orcid.org/0000-0001-9015-9864
Gao, Hongyu
Liu, Yunlong https://orcid.org/0000-0002-2699-626X
Moore, Drew https://orcid.org/0009-0005-0926-0874
Subramanian, Suganya https://orcid.org/0009-0007-2822-9420
Berto, Stefano https://orcid.org/0000-0001-9028-9458
Gopalakrishnapillai, Anilkumar
Barwe, Sonali P. https://orcid.org/0000-0003-4162-3004
Guo, Hongfen
Cheung, Nai-Kong V. https://orcid.org/0000-0001-6323-5171
Kapur, Reuben https://orcid.org/0000-0003-2225-1700
Paczesny, Sophie https://orcid.org/0000-0001-5571-2775
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA232491, P30 CA138313)
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 27 June 2025
First Online: 21 July 2025
Competing interests
: N.-K.V.C. reports receiving commercial research grants from Y-mAbs Therapeutics and Abpro-Labs Inc., holding ownership interest/equity in Y-mAbs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. N.-K.V.C. is the inventor and owner of issued patents licensed by Memorial Sloan Kettering Cancer Center (MSKCC) to Y-mAbs Therapeutics, Biotec Pharmacon, and Abpro-labs. Both MSKCC and N.-K.V.C. have financial interests in Y-mAbs. N.-K.V.C. is an advisory board member for Abpro-Labs and Eureka Therapeutics. Otherwise, the authors declare that they have no competing interests.
